Response to mepolizumab treatment is sustained across 4-weekly dosing periods.

Pavord, Ian D; Bleecker, Eugene R; Buhl, Roland; Chanez, Pascal; Bel, Elisabeth H; Howarth, Peter; Bratton, Daniel J; Albers, Frank C; Yancey, Steven

Pavord, Ian D; Bleecker, Eugene R; Buhl, Roland; Chanez, Pascal; Bel, Elisabeth H; Howarth, Peter; Bratton, Daniel J; Albers, Frank C; Yancey, Steven.

Afiliación

Pavord ID; Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
Bleecker ER; Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USA.
Buhl R; Dept of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.
Chanez P; Clinique des bronches allergies et sommeil, INSERM C2VN Center and CIC Nord APHM, Aix-Marseille University, Marseille, France.
Bel EH; Dept of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Howarth P; Global Medical Franchise, GSK, Brentford, UK.
Bratton DJ; Clinical Statistics, GSK, Stockley Park, UK.
Albers FC; Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA.
Yancey S; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.

ERJ Open Res ; 6(3)2020 Jul.

Article en En | MEDLINE | ID: mdl-32963999

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: ERJ Open Res Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google